Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

德克萨斯州奥斯汀讯——Natera, Inc.（纳斯达克股票代码：NTRA）的联合创始人兼董事Sheena Jonathan最近进行了一系列股票交易，这在最近的SEC文件中披露。Natera是一家过去一年股价飙升超过158%，目前市值227亿美元的公司。根据 InvestingPro ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

T he analyst from Canaccord Genuity noted Guardant Health (NASDAQ:GH)'s extensive experience in blood-based cancer detection as a competitive advantage, even as Natera (NASDAQ:NTRA) continues to ...

Guardant Health is a leader in liquid biopsy ... and Guardant commands the second-largest market share after the market leader Natera. Reveal’s differentiating feature is that it is "tumor ...

Is Guardant Health (GH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $60 from $42 and keeps a Buy rating on the shares. The firm said they remain bullish after a strong finish ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health wrapped up 2024 on a high note, delivering 31% ...